Doravirine/lamivudine/tenofovir

Doravirine/lamivudine/tenofovir, sold under the brand name Delstrigo, is a fixed-dose combination antiretroviral medication for the treatment of HIV/AIDS.^[4][6] It contains doravirine, lamivudine, and tenofovir disoproxil.^[7][6] It is taken by mouth.^[4]

Doravirine/lamivudine/tenofovir

Combination of
Doravirine	Non-nucleoside reverse transcriptase inhibitor
Lamivudine	Nucleoside reverse transcriptase inhibitor
Tenofovir disoproxil	Nucleotide reverse transcriptase inhibitor
Clinical data
Trade names	Delstrigo
Other names	MK-1439A
AHFS/Drugs.com	Monograph
MedlinePlus	a618049
License data	US DailyMed: Delstrigo
Routes of administration	By mouth
ATC code	J05AR24 (WHO)
Legal status
Legal status	AU: S4 (Prescription only) CA: ℞-only[1][2] UK: POM (Prescription only)[3] US: ℞-only[4] EU: Rx-only[5]
Identifiers
CAS Number	2446159-50-6
KEGG	D11396

In the United States, it was approved by the Food and Drug Administration (FDA) for the treatment of HIV-1 infection in August 2018.^[7][8][9]